These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31435903)

  • 1. Inhibiting exosomal MIC-A and MIC-B shedding of cancer cells to overcome immune escape: new insight of approved drugs.
    Moloudizargari M; Asghari MH; Mortaz E
    Daru; 2019 Dec; 27(2):879-884. PubMed ID: 31435903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Autophagy in the Tumor Microenvironment: New Challenges and Opportunities for Regulating Tumor Immunity.
    Janji B; Berchem G; Chouaib S
    Front Immunol; 2018; 9():887. PubMed ID: 29922284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exosome mediated communication within the tumor microenvironment.
    Milane L; Singh A; Mattheolabakis G; Suresh M; Amiji MM
    J Control Release; 2015 Dec; 219():278-294. PubMed ID: 26143224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
    Kim N; Kim HS
    Front Immunol; 2018; 9():2041. PubMed ID: 30250471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer Exosomes as Conveyors of Stress-Induced Molecules: New Players in the Modulation of NK Cell Response.
    Vulpis E; Soriani A; Cerboni C; Santoni A; Zingoni A
    Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30708970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer group 2D receptor and its ligands in cancer immune escape.
    Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
    Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human NK cells: From surface receptors to clinical applications.
    Moretta L; Pietra G; Vacca P; Pende D; Moretta F; Bertaina A; Mingari MC; Locatelli F; Moretta A
    Immunol Lett; 2016 Oct; 178():15-9. PubMed ID: 27185471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies.
    Matosevic S
    J Immunol Res; 2018; 2018():4054815. PubMed ID: 30306093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NK cells to cure cancer.
    Di Vito C; Mikulak J; Zaghi E; Pesce S; Marcenaro E; Mavilio D
    Semin Immunol; 2019 Feb; 41():101272. PubMed ID: 31085114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective.
    Cifaldi L; Locatelli F; Marasco E; Moretta L; Pistoia V
    Trends Mol Med; 2017 Dec; 23(12):1156-1175. PubMed ID: 29133133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD8
    Farhood B; Najafi M; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting natural killer cells in cancer immunotherapy.
    Guillerey C; Huntington ND; Smyth MJ
    Nat Immunol; 2016 Aug; 17(9):1025-36. PubMed ID: 27540992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imbalance of NKG2D and its inhibitory counterparts: how does tumor escape from innate immunity?
    Zhang C; Zhang J; Wei H; Tian Z
    Int Immunopharmacol; 2005 Jul; 5(7-8):1099-111. PubMed ID: 15914316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tricking the balance: NK cells in anti-cancer immunity.
    Pahl J; Cerwenka A
    Immunobiology; 2017 Jan; 222(1):11-20. PubMed ID: 26264743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sialic Acid Blockade Suppresses Tumor Growth by Enhancing T-cell-Mediated Tumor Immunity.
    Büll C; Boltje TJ; Balneger N; Weischer SM; Wassink M; van Gemst JJ; Bloemendal VR; Boon L; van der Vlag J; Heise T; den Brok MH; Adema GJ
    Cancer Res; 2018 Jul; 78(13):3574-3588. PubMed ID: 29703719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human tumor-derived exosomes down-modulate NKG2D expression.
    Clayton A; Mitchell JP; Court J; Linnane S; Mason MD; Tabi Z
    J Immunol; 2008 Jun; 180(11):7249-58. PubMed ID: 18490724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural Killer-Derived Exosomal miR-186 Inhibits Neuroblastoma Growth and Immune Escape Mechanisms.
    Neviani P; Wise PM; Murtadha M; Liu CW; Wu CH; Jong AY; Seeger RC; Fabbri M
    Cancer Res; 2019 Mar; 79(6):1151-1164. PubMed ID: 30541743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [EXOSOMES AS MEDIATORS OF INTERCELLULAR COMMUNICATION: THE CANCER AND TELOMERASE CONNECTION].
    Uziel O; Gutkin A; Beery E; Lahav M
    Harefuah; 2017 Nov; 156(11):710-714. PubMed ID: 29198089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications.
    Chitadze G; Bhat J; Lettau M; Janssen O; Kabelitz D
    Scand J Immunol; 2013 Aug; 78(2):120-9. PubMed ID: 23679194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Negative regulation of tumor-infiltrating NK cell in clear cell renal cell carcinoma patients through the exosomal pathway.
    Xia Y; Zhang Q; Zhen Q; Zhao Y; Liu N; Li T; Hao Y; Zhang Y; Luo C; Wu X
    Oncotarget; 2017 Jun; 8(23):37783-37795. PubMed ID: 28384121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.